Endpoints News 生物医药· ENDPOINTS·· 2026-10-07AI 评分31
Nuvig Therapeutics 终止一项 II 期试验;Cerevance 报告帕金森病进展
Nuvig drops a Phase 2 trial; Cerevance reports Parkinson's progress
AI 导读
Nuvig Therapeutics 终止两项试验中的一项,砍掉一项 II 期研究;Cerevance 报告帕金森病进展。报道还提及 RevMed、Tang Capital、GSK 和 AmyriAD Therapeutics 的相关消息。
正文
Plus news about RevMed, Tang Capital, GSK and AmyriAD Therapeutics.
Nuvig Therapeutics ends one of two trials: The biotech axed a Phase 2 study of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news